Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional Response Criteria

被引:50
作者
Bonekamp, Susanne [1 ]
Li, Zhen [1 ]
Geschwind, Jean-Francois H. [1 ]
Halappa, Vivek Gowdra [1 ]
Corona-Villalobos, Celia Pamela [1 ]
Reyes, Diane [1 ]
Pawlik, Timothy M. [2 ]
Bonekamp, David [1 ]
Eng, John [1 ]
Kamel, Ihab R. [1 ]
机构
[1] Johns Hopkins Univ Hosp, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Surg & Oncol, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; TUMOR RESPONSE; HISTOPATHOLOGIC CORRELATION; LIVER METASTASES; END-POINTS; SURVIVAL; CANCER; RECIST; QUANTIFICATION; MANAGEMENT;
D O I
10.1148/radiol.13122307
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
100231 [临床病理学]; 100902 [航空航天医学];
摘要
Purpose: To identify and validate the optimal thresholds for volumetric functional MR imaging response criteria to predict overall survival after intraarterial treatment (IAT) in patients with unresectable hepatocellular carcinoma (HCC). Materials and Methods: Institutional review board approval and waiver of informed consent were obtained. A total of 143 patients who had undergone MR imaging before and 3-4 weeks after the first cycle of IAT were included. MR imaging analysis of one representative HCC index lesion was performed with proprietary software after initial treatment. Subjects were randomly divided into training (n = 114 [79.7%]) and validation (n = 29 [20.3%]) data sets. Uni- and multivariate Cox models were used to determine the best cutoffs, as well as survival differences, between response groups in the validation data set. Results: Optimal cutoffs in the training data set were 23% increase in apparent diffusion coefficient (ADC) and 65% decrease in volumetric enhancement in the portal venous phase (VE). Subsequently, 25% increase in ADC and 65% decrease in VE were used to stratify patients in the validation data set. Comparison of ADC responders (n = 12 [58.6%]) with non-responders (n = 17 [34.5%]) showed significant differences in survival (25th percentile survival, 11.2 vs 4.9 months, respectively; P = .008), as did VE responders (n = 9 [31.0%]) compared with non-responders (n = 20 [69.0%]; 25th percentile survival, 11.5 vs 5.1 months, respectively; P = .01). Stratification of patients with a combination of the criteria resulted in significant differences in survival between patients with lesions that fulfilled both criteria (n = 6 [20.7%]; too few cases to determine 25th percentile), one criterion (n = 9 [31.0%]; 25th percentile survival, 6.0 months), and neither criterion (n = 14 [48.3%]; 25th percentile survival, 5.1 months; P = .01). The association between the two criteria and overall survival remained significant in a multivariate analysis that included age, sex, Barcelona Clinic for Liver Cancer stage, and number of follow-up treatments. Conclusion: After IAT for unresectable HCC, patients can be stratified into significantly different survival categories based on responder versus nonresponder status according to MR imaging ADC and VE cutoffs. (c) RSNA, 2013
引用
收藏
页码:420 / 430
页数:11
相关论文
共 40 条
[1]
Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[2]
Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations [J].
不详 .
NEOPLASIA, 2009, 11 (02) :102-125
[3]
[Anonymous], 1979, HDB REP RES CANC TRE
[4]
[Anonymous], P 17 M INT SOC MAGN
[5]
Multimodality imaging following 90Y radioembolization:: A comprehensive review and pictorial essay [J].
Atassi, Bassel ;
Bangash, Affaan K. ;
Bahram, Ammar ;
Pizzi, Giuseppi ;
Lewandowski, Robert J. ;
Ryu, Robert K. ;
Sato, Kent T. ;
Gates, Vanessa L. ;
Mulcahy, Mary F. ;
Kulik, Laura ;
Miller, Frank ;
Yaghmai, Vahid ;
Murth, Ravi ;
Larson, Andrew ;
Omary, Reed A. ;
Salem, Riad .
RADIOGRAPHICS, 2008, 28 (01) :81-99
[6]
Hepatocellular Carcinoma : Response to TACE Assessed with Semiautomated Volumetric and Functional Analysis of Diffusion-weighted and Contrast-enhanced MR Imaging Data [J].
Bonekamp, Susanne ;
Jolepalem, Prashant ;
Lazo, Mariana ;
Gulsun, Mehmet Akif ;
Kiraly, Atilla P. ;
Kamel, Ihab R. .
RADIOLOGY, 2011, 260 (03) :752-761
[7]
Clinical management of hepatocellular carcinoma.: Conclusions of the Barcelona-2000 EASL Conference [J].
Bruix, J ;
Sherman, M ;
Llovet, JM ;
Beaugrand, M ;
Lencioni, R ;
Burroughs, AK ;
Christensen, E ;
Pagliaro, L ;
Colombo, M ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2001, 35 (03) :421-430
[8]
Review article: the management of hepatocellular carcinoma [J].
Cabrera, R. ;
Nelson, D. R. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (04) :461-476
[9]
Transarterial chemoembolization for unresectable hepatocellular carcinoma:: Meta-analysis of randomized controlled trials [J].
Cammà, C ;
Schepis, F ;
Orlando, A ;
Albanese, M ;
Shahied, L ;
Trevisani, F ;
Andreone, P ;
Craxì, A ;
Cottone, M .
RADIOLOGY, 2002, 224 (01) :47-54
[10]
Hepatic Tumors: Region-of-Interest versus Volumetric Analysis for Quantification of Attenuation at CT [J].
Chalian, Hamid ;
Tochetto, Sandra M. ;
Toere, Hueseyin G. ;
Rezai, Pedram ;
Yaghmai, Vahid .
RADIOLOGY, 2012, 262 (03) :853-861